🇺🇸 Levodopa Benserazide Madopar in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Unevaluable Event — 2 reports (18.18%)
  2. Asthenia — 1 report (9.09%)
  3. Bradykinesia — 1 report (9.09%)
  4. Cerebrovascular Accident — 1 report (9.09%)
  5. Cervical Spinal Stenosis — 1 report (9.09%)
  6. Communication Disorder — 1 report (9.09%)
  7. Constipation — 1 report (9.09%)
  8. Craniofacial Fracture — 1 report (9.09%)
  9. Decreased Appetite — 1 report (9.09%)
  10. Duodenitis — 1 report (9.09%)

Source database →

Other Neurology approved in United States

Frequently asked questions

Is Levodopa Benserazide Madopar approved in United States?

Levodopa Benserazide Madopar does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Levodopa Benserazide Madopar in United States?

IRCCS San Raffaele Roma is the originator. The local marketing authorisation holder may differ — check the official source linked above.